Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

ANNALS OF HUMAN GENETICS is a distinguished peer-reviewed journal extensively covering the field of genetics, published by Wiley. Established in 1954 and extending its influence into 2024, this journal features comprehensive research articles, reviews, and case studies aimed at advancing our understanding of human genetic conditions and their implications on health. With its ISSN number 0003-4800 and E-ISSN 1469-1809, the journal has carved a prominent niche within the academic community, currently ranking in the third quartile in both genetic and clinical genetics categories (Q3, 2023). Its Scopus rankings reflect its credibility, placing it #54 out of 99 in clinical genetics. Though it is not open access, it remains an essential resource for researchers and practitioners seeking to explore the latest findings and methodologies in genetics, serving as a critical platform for knowledge dissemination and dialogue within the scientific community. As we delve deeper into the complexities of our genetic makeup, the ANNALS OF HUMAN GENETICS continues to play a vital role in fostering innovation and collaboration in this ever-evolving field.

Molecular Genetics Microbiology and Virology is an esteemed academic journal published by PLEIADES PUBLISHING INC, specializing in the complex interplay of genetics, microbiology, and virology. Established in 2007, this journal serves as a crucial platform for researchers and professionals committed to advancing our understanding of infectious diseases and molecular biology. Despite its current categorization in Q4 across several fields, the journal aims to evolve and foster significant discourse within the scientific community. While not an open access journal, it provides essential insights and high-quality research articles that contribute to the body of knowledge in molecular genetics and related disciplines. Located in the vibrant research landscape of New York, USA, the journal also encourages new submissions that address cutting-edge research topics and emerging trends in infectious diseases, thereby appealing to both emerging scholars and seasoned experts alike.

JOURNAL OF NEUROGENETICS, published by Taylor & Francis Ltd in the United Kingdom, is an influential platform for research and discussion in the dynamic field of neurogenetics. With an ISSN of 0167-7063 and an E-ISSN of 1563-5260, this journal has been committed to advancing our understanding of the genetic underpinnings of neurological conditions since its inception in 1983. Presently categorized in the Q3 quartile for Cellular and Molecular Neuroscience and Q2 for Genetics as of 2023, it serves as an essential resource for researchers and professionals seeking insights into the genetic factors influencing nervous system function and disorder. Although it does not offer open access, the journal remains a critical repository of knowledge with a broad scope that invites contributions spanning molecular genetics to neurobiology. With its rankings in Scopus reflecting a keen focus on robust academic standards, the JOURNAL OF NEUROGENETICS is vital for those dedicated to pioneering research and finding solutions in neurogenetics, making it a significant asset to students, scholars, and industry experts alike.

Human Gene is an innovative open access journal published by ELSEVIER, dedicated to the ever-evolving field of genetics. Established in 2022, this journal serves as a vital resource for researchers, professionals, and students alike, aiming to facilitate the dissemination of groundbreaking research and advancements in both basic and clinical genetics. With an ISSN of 2773-0441, Human Gene focuses on providing a platform for high-quality studies that investigate genetic mechanisms, their implications in health and disease, and novel therapeutic strategies. The journal currently holds a Q4 ranking in both Genetics and Clinical Genetics categories, reflecting its emerging status within the scientific community, and strives to enhance its impact to better serve an engaged audience. With its base in Amsterdam, Netherlands, Human Gene is committed to making research accessible through its open access model, inviting contributions that advance our understanding of human genetics and foster collaboration across disciplines.

PLoS Genetics, published by the PUBLIC LIBRARY SCIENCE, is a leading open-access journal dedicated to advancing the field of genetics, molecular biology, and related disciplines. With its ISSN of 1553-7404, this esteemed journal has been offering unrestricted access to its content since 2005, fostering a global community of researchers, professionals, and students. Situated in the United States, its contributions can be found at 1160 Battery Street, Ste 100, San Francisco, CA 94111. As of 2023, PLoS Genetics proudly holds a Q1 ranking in multiple categories including Cancer Research, Ecology, Evolution, Behavior and Systematics, Genetics, and Molecular Biology, underscoring its impact in these vital scientific areas. The journal's commitment to disseminating high-quality research is reflected in its impressive Scopus rankings, with notable positions in various fields of study, ensuring that it remains a crucial resource for cutting-edge research and innovation. By providing an open-access platform, PLoS Genetics not only enhances the visibility of genetic research but also encourages collaborations and the sharing of knowledge that can lead to significant breakthroughs in science.

Annual Review of Genomics and Human Genetics, published by ANNUAL REVIEWS, represents a pivotal platform in the field of Genetics and Molecular Biology. With an impressive impact factor reflecting its high citation rate and scholarly influence, this journal is renowned for its authoritative reviews that synthesize current research across genomics and human genetics. Highlighting its Q1 category rankings in both Genetics and Clinical Genetics, as well as its ranking within the top tiers of Biochemistry and Genetics, the journal stands out as a leading resource for researchers, professionals, and students eager to stay abreast of groundbreaking developments in these rapidly evolving fields. While not currently an open access journal, its rigorous peer-review process ensures the highest standards of scientific integrity. Researchers can access comprehensive reviews that delve into both fundamental genetics concepts and cutting-edge discoveries, making it an essential resource for advancing understanding in human genetics and its applications.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

CURRENT ISSUES IN MOLECULAR BIOLOGY, published by MDPI, serves as an essential forum for researchers and professionals in the rapidly evolving field of molecular biology. Established in 1999 and operating under an Open Access model, this journal not only shares high-quality research but also encourages a vibrant exchange of ideas across various disciplines, including medicine and microbiology. With an impressive trajectory leading into 2024, it has earned its place in the Q2 quartile for both Medicine (miscellaneous) and Microbiology, emphasizing its relevance and impact in these areas. The journal’s commitment to disseminating cutting-edge findings is reflected in its diverse coverage of topics, from molecular genetics to microbial interactions. Operating from its home base in Basel, Switzerland, CURRENT ISSUES IN MOLECULAR BIOLOGY is positioned to contribute significantly to the academic landscape, making it indispensable for those seeking to advance their understanding and research within the life sciences.

MUTAGENESIS, published by Oxford University Press, is a leading journal in the fields of genetics, toxicology, and health, dedicated to advancing our understanding of mutagenic processes and their implications for human health. With an ISSN of 0267-8357 and an E-ISSN of 1464-3804, this journal has been at the forefront of mutagenesis research since its inception in 1986 and will continue to publish cutting-edge studies until 2024. Holding an impressive position in the academic community, MUTAGENESIS is ranked Q2 in Genetics, Q2 in Clinical Genetics, Q2 in Health, Toxicology, and Mutagenesis, and Q1 in Toxicology, reflecting its commitment to high-quality scholarly work. The journal enjoys a robust global readership, with significant rankings in various Scopus categories, including top positions in Environmental Science and Clinical Genetics, ensuring that it remains a vital resource for researchers, professionals, and students alike. While access to its articles is not completely open, MUTAGENESIS provides valuable insights that fuel innovative research and drive forward the understanding of genetic risks and toxicological assessments.